ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

CDXS Codexis Inc

3.55
0.25 (7.58%)
20 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Codexis Inc NASDAQ:CDXS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.25 7.58% 3.55 3.42 3.70 3.6599 3.31 3.31 645,856 01:00:00

Codexis to Participate in Jefferies Healthcare Conference

24/05/2023 9:05pm

GlobeNewswire Inc.


Codexis (NASDAQ:CDXS)
Historical Stock Chart


From Jul 2022 to Jul 2024

Click Here for more Codexis Charts.

Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the Jefferies Healthcare Conference, being held June 7-9, 2023, in New York, New York.

Management will participate in a fireside chat on Wednesday, June 7, 2023, at 1:00 pm ET. A live webcast of the event will be available in the Investor Relations section of the Company’s website, http://ir.codexis.com. A replay will be archived for 90 days following the event.

About Codexis

Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® technology platform to discover, develop and enhance novel, high-performance enzymes and other classes of proteins. Codexis enzymes solve for real-world challenges associated with small molecule pharmaceuticals manufacturing, nucleic acid synthesis and genomic sequencing, and – as biotherapeutic candidates – they have the potential to treat challenging diseases. Codexis’ unique enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing, greater sensitivity in genomic and diagnostic applications and potentially more efficacious therapeutics. For more information, visit www.codexis.com.

For More Information

Investor ContactCarrie McKim(336) 608-9706ir@codexis.com

Media ContactLauren Musto(781) 572-1147media@codexis.com

1 Year Codexis Chart

1 Year Codexis Chart

1 Month Codexis Chart

1 Month Codexis Chart

Your Recent History

Delayed Upgrade Clock